Clinical Trials Logo

Recurrent Malignant Gliomas clinical trials

View clinical trials related to Recurrent Malignant Gliomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT00848523 Terminated - Clinical trials for Recurrent Malignant Gliomas

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The drug LBH589 (panobinostat) is an experimental (investigational) drug that is being tested for recurrent (returning) malignant gliomas. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). It belongs to a new class of drugs called "histone deacetylase inhibitors." Histones are proteins located in the nucleus of cells that bind to DNA, the chemical that makes up genes. These proteins help control which genes are turned "on" and "off." Studies have shown that drugs like panobinostat (LBH589) may lead to tumor cell death.

NCT ID: NCT00595322 Completed - Brain Cancer Clinical Trials

Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma

Start date: December 2005
Phase: N/A
Study type: Interventional

This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted. This study will also give us some information about whether the combination of Bevacizumab and radiation has potential to become an effective treatment for regrowing brain tumors. Bevacizumab is an experimental drug that blocks a molecule called VEGF that is found in high amounts in malignant gliomas. VEGF promotes the growth of blood vessels that bring nutrients to tumor cells. In studies with laboratory animals, Bevacizumab slowed the growth of several different types of human cancer cells by blocking the effects of VEGF. There is also evidence that Bevacizumab enhances the effects of radiation on tumor cell